Our assessment
Pfizer's post-COVID business is improving enough to support a selective value buy, but the turnaround remains incomplete. Non-COVID products grew 7% operationally in the latest quarter, while total revenue was roughly flat. At about 10 times guided adjusted earnings, the price leaves room for modest progress; the investment should depend on profitable portfolio renewal rather than a return to pandemic revenue.
Research updated November 4, 2026; historical price references end at the November 3 regular-session close.
The relevant growth engine is now outside the pandemic products
The latest results distinguish the portfolio investors should value from the unusual COVID surge. Excluding Comirnaty and Paxlovid, Pfizer reported 7% operational revenue growth, with launched and acquired products growing more quickly. That is evidence of a commercial business capable of developing new sources of demand. It also provides a more useful basis for a long-term holding than assuming recurring pandemic-scale orders. I regard the change as constructive because it makes the turnaround depend increasingly on ordinary pharmaceutical adoption rather than an exceptional public-health event.
Growth must still offset mature products and investment costs
The total-company result was much less impressive than the growth of selected newer medicines. That is why the post-COVID transition should not be declared complete. Mature products, exclusivity losses and changing product mix can absorb part of each launch's contribution. Cost reductions help earnings, but acquisitions and research spending must eventually earn acceptable returns. Investors own the whole portfolio and its financial obligations, not just the fastest-growing product subset. The company needs a sustainable combination of commercial renewal and expense discipline rather than another temporary revenue windfall.
The stock offers value with a specific qualification
At the saved price, Pfizer's guided adjusted earnings multiple does not require the same growth assumptions as a premium obesity franchise. That is the main reason I favor a measured purchase. The discount is also understandable: future earning power and capital allocation remain uncertain. I would buy for a gradual improvement in non-COVID earnings, while avoiding a position dependent on every acquisition succeeding or the dividend being immune to cash pressure. The transition is investable at a restrained valuation, but it remains a turnaround rather than a completed return to predictable growth.
The financial evidence behind this view
Latest verified report: Pfizer latest quarterly financial results, published 2026-11-03. Measures retain their stated accounting basis and reporting periods.
| Reported measure | Value and period | Comparison and meaning |
|---|---|---|
| Revenue | USD 16.583 billion Quarter ended 2026-09-27 |
USD 16.654 billion (2025-09-28). -0.43% change. Reported GAAP; quarter and balance dates remain separate. Source |
| Net income attributable to parent | USD 3.242 billion Quarter ended 2026-09-27 |
USD 3.541 billion (2025-09-28). -8.44% change. Reported GAAP; quarter and balance dates remain separate. Source |
| GAAP diluted EPS | USD/shares 0.56 Quarter ended 2026-09-27 |
USD/shares 0.62 (2025-09-28). -9.68% change. Reported GAAP; quarter and balance dates remain separate. Source |
| Cash and cash equivalents at period end | USD 1.824 billion 2026-09-27 balance |
USD 1.343 billion (2025-09-28). Reported GAAP; quarter and balance dates remain separate. Source |
What the valuation does and does not say
[object Object]
Forward guidance multiple, not trailing GAAP P/E. Company-defined adjustments and execution risk apply.
Frequently asked questions
Did non-COVID products grow?
Yes. Pfizer reported 7% operational growth excluding Comirnaty and Paxlovid in Q3 2026.
Does that mean the total company grew 7%?
No. Total revenue was roughly flat because the portfolio includes the COVID products and other differences.
What is the investment conclusion?
A selective value buy with patience and limited position size, based on portfolio renewal at a low guided adjusted earnings multiple.
Discuss the investment case
Join the existing WhatsApp research discussion to compare the business case, valuation and risks. Group participation does not guarantee returns or access to personalized advice.
Sources
Investment opinion for general education, not personalized financial advice. Capital is at risk. Financial observations are dated; estimates and hypothetical examples do not guarantee future returns.